Digest Network Come funziona
Network
/
Società
LE
Non verificato

LEO Pharma Inc.

Di cosa scriviamo

EventiFarmaceuticaIndustriaSaluteSanità

7 comunicati stampa

Guarda tutti i comunicati
24/10/2025
Eventi
Analisi di mercato
Sanità
Farmaceutica
Salute
LEO Pharma Unveils Data on the U.S. Prevalence of Chronic Hand Eczema at Fall Clinical Dermatology Conference
Fonte
LEO Pharma Inc.
Emittente
Business Wire
1.00
0
23/07/2025
ANZUPGO® (delgocitinib) Cream Is Now the First and Only FDA-Approved Treatment for Moderate-to-Severe Chronic Hand Eczema (CHE) in Adults
Fonte
LEO Pharma Inc.
Emittente
Business Wire
1.00
0
05/03/2025
Eventi
Analisi di mercato
Salute
Sanità
Scienza
Farmaceutica
LEO Pharma Survey: Dermatology Providers Say Chronic Hand Eczema Is Widely Misunderstood and Inadequately Managed
Fonte
LEO Pharma Inc.
Emittente
Business Wire
1.00
0
25/10/2024
Eventi
Industria
Salute
Scienza
Farmaceutica
Medicina - Varie
LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry® Trial (tralokinumab-ldrm) in Patients with Moderate-to-Severe Atopic Dermatitis (AD) at Fall Clinical 2024
Fonte
LEO Pharma Inc.
Emittente
Business Wire
1.00
0
23/10/2024
Eventi
Industria
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Sanità
LEO Pharma Presents Adbry® (tralokinumab-ldrm) and Delgocitinib Cream Data at 2024 Fall Clinical Dermatology Conference
Fonte
LEO Pharma Inc.
Emittente
Business Wire
1.00
0
22/10/2024
Industria
Comunicazione
Marketing
Medicina - Varie
Management
Sanità
Farmaceutica
Salute
LEO Pharma Launches Talk to the Hand Campaign to Raise Awareness of the Impact of Chronic Hand Eczema
Fonte
LEO Pharma Inc.
Emittente
Business Wire
1.00
0
17/09/2024
Industria
Sanità
Farmaceutica
Salute
Adbry® (tralokinumab-ldrm) Autoinjector Now Available for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD) in the U.S.
Fonte
LEO Pharma Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0